(:PRTK)

Oct 05, 2023 08:00 am ET
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and...
Sep 21, 2023 08:58 am ET
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical...
Sep 18, 2023 09:37 am ET
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
Sep 12, 2023 07:30 am ET
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
Sep 10, 2023 08:06 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, KLR, PRTK
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Heritage-Crystal Clean, Inc. (NASDAQ:...
Sep 07, 2023 03:34 pm ET
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
Aug 27, 2023 12:06 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CEQP, CELL, DINO, PRTK
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Crestwood Equity Partners LP (NYSE:...
Aug 25, 2023 02:47 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ: PRTK) stock prior to June 7, 2023. You are hereby notified...
Aug 09, 2023 02:37 pm ET
Investor Alert: Abbott Cooper PLLC Announces Investigation into Paratek Pharmaceuticals, Inc.; Urges Paratek Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC announces that it is investigating Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) (“Paratek” or the “Company”) on behalf of the Company’s investors.
Aug 08, 2023 12:13 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ: PRTK) stock prior to June 7, 2023. You are hereby notified that Levi &...
Aug 03, 2023 08:00 am ET
Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), (“Paratek” or “the Company”), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public...
Aug 02, 2023 05:36 pm ET
Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
Jul 19, 2023 05:26 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, FRG, PRTK, SYNH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CIRCOR International, Inc. (NYSE:...
Jul 18, 2023 03:28 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Paratek Pharmaceuticals, Inc. by Gurnet Point Capital
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. ("Paratek" or the "Company") (NASDAQ: PRTK) stock prior to June 7, 2023. You are hereby notified that Levi &...
Jul 18, 2023 10:40 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRTK, PTEN, NEX, BG
NEW YORK, July 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 17, 2023 05:06 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – PRTK, QUOT, CWBR, NEX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 12, 2023 03:55 pm ET
Jul 11, 2023 04:15 pm ET
Jul 11, 2023 06:42 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, PTEN, NEX, PRTK
NEW YORK, July 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 10, 2023 09:30 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – CFMS, PRTK, NETI, WMC
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Jul 10, 2023 08:00 am ET
Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 29, 2023 12:13 pm ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates WMC, SGTX, PRTK
NEW YORK, June 29, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 28, 2023 10:35 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – SYNH, AAIC, PRTK, NEX
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jun 27, 2023 12:01 pm ET
Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
Jun 27, 2023 08:00 am ET
European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 27, 2023 08:00 am ET
NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital
Intends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meeting Citing the Board's Failure to Hold Management Accountable for Years of Underperformance
Jun 22, 2023 10:19 am ET
IMPORTANT ALERT: Halper Sadeh LLC Investigates PRTK, NETI, DICE, QUOT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Paratek Pharmaceuticals, Inc. (NASDAQ:...
Jun 21, 2023 07:40 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – PRTK, NEX, SYNH, AAIC
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jun 21, 2023 01:12 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates QUOT, PRTK, TESS, HMPT
NEW YORK, June 21, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 20, 2023 09:17 am ET
PRTK Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Paratek Pharmaceuticals to Gurnet Point Capital and Novo Holdings
The law firm of Wohl & Fruchter LLP is investigating the fairness of the $2.15 per share in cash, plus a contingent value right (CVR), at which Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) (“Paratek”) has agreed to be sold to Gurnet Point Capital...
Jun 17, 2023 12:29 am ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger - PRTK, KDNY, BG, WTT
NEW YORK, June 17, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Jun 15, 2023 09:44 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, AAIC, PRTK, INFI
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: VectivBio Holding AG (NASDAQ: VECT)’s...
Jun 14, 2023 05:24 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – KDNY, PRTK, WTT, BG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jun 12, 2023 01:49 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CIR, PRTK, KDNY
NEW YORK, June 12, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jun 12, 2023 08:00 am ET
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 11, 2023 12:12 am ET
PRTK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Paratek Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) to Gurnet Point Capital and Novo Holdings A/S is fair to Paratek shareholders. Under the terms of the agreement, Paratek shareholders will receive $2.15 per share in cash, plus a Contingent Value Right of $0.85 per share payable upon the achievement of $320 million in U.S. NUZYRA net sales (excluding certain permitted deductions, payments under Paratek’s contract with ASPR-BARDA, certain government payments and certain royalty revenue) in any calendar year ending on
Jun 10, 2023 08:11 pm ET
Lifshitz Law PLLC Announces Investigations of PRTK, CIR, REUN, and FATE
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of PRTK to Gurnet Point Capital and Novo Holdings A/S for $2.15 per share in cash, plus...
Jun 08, 2023 12:25 am ET
Shareholder Alert: Ademi LLP investigates whether Paratek Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Gurnet Point Capital and Novo Holdings
MILWAUKEE, June 8, 2023 /PRNewswire/ -- Ademi LLP is investigating Paratek (Nasdaq: PRTK) for possible breaches of fiduciary duty and other violations of law in its transaction with Gurnet Point Capital and Novo Holdings. 
Jun 06, 2023 09:05 am ET
Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today...
May 09, 2023 04:05 pm ET
Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 01, 2023 08:30 am ET
Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Tuesday, May 9 at 4:30 p.m. EDT to report financial results for first quarter 2023.The audio webcast can be accessed...
Apr 10, 2023 07:30 am ET
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 20
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Mar 16, 2023 07:30 am ET
Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2022. Paratek generated total revenue of $160.3 million, primarily...
Mar 08, 2023 08:30 am ET
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, March 16, 2023 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth...
Mar 01, 2023 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Feb 01, 2023 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jan 18, 2023 07:00 am ET
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List...
Jan 05, 2023 08:00 am ET
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract with the Biomedical...
Dec 20, 2022 07:30 am ET
Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected...
Dec 19, 2022 07:30 am ET
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating NUZYRA’s effectiveness in the treatment of pulmonary anthrax. In the study, a 100% survival rate was observed in...
Dec 01, 2022 05:45 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Nov 21, 2022 04:05 pm ET
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Nov 03, 2022 04:05 pm ET
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2022. "We are pleased to report another strong quarter of growth in NUZYRA’s core...
Nov 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Nov 01, 2022 08:00 am ET
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Oct 31, 2022 08:00 am ET
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in...
Oct 25, 2022 08:00 am ET
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30 p.m. ET to report its financial results for the third quarter of 2022. The audio webcast...
Oct 13, 2022 04:05 pm ET
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Oct 03, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Sep 26, 2022 08:30 am ET
Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Sep 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Sep 01, 2022 08:00 am ET
Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 03, 2022 04:05 pm ET
Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended June 30, 2022. “The strong year-over-year growth of NUZYRA’s core commercial business is a...
Aug 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jul 25, 2022 04:05 pm ET
Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, Aug. 3 at 4:30 p.m. ET to report its financial results for the second quarter of 2022. The audio webcast...
Jul 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 21, 2022 04:05 pm ET
Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacte
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced the U.S. Food and Drug Administration has granted Fast Track designation for the oral and IV formulations of the company’s novel, broad-spectrum antibiotic NUZYRA® (omadacycline) for the...
Jun 01, 2022 04:15 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 01, 2022 04:05 pm ET
Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 16, 2022 04:05 pm ET
Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 04, 2022 04:05 pm ET
Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. “Our commercial execution continues to be strong, as demonstrated by the 51%...
May 02, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Apr 26, 2022 04:05 pm ET
Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Wednesday, May 4 at 4:30 p.m. ET to report its financial results for the first quarter of 2022. The audio webcast...
Apr 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Mar 14, 2022 07:30 am ET
Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the fourth quarter and full-year ended December 31, 2021. “We are extremely proud of the 76% year-over-year growth in...
Mar 08, 2022 04:05 pm ET
Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex
Paratek Pharmaceuticals, Inc. announced today the publication of data from an investigator-initiated study evaluating the activity of NUZYRA® (omadacycline) in a dynamic hollow fiber model of Mycobacterium avium complex (MAC) pulmonary infection....
Mar 02, 2022 04:05 pm ET
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter...
Mar 01, 2022 04:05 pm ET
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member
Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus’ Board of Directors...
Mar 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Feb 01, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jan 03, 2022 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Dec 16, 2021 11:36 am ET
China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections 
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of...
Dec 01, 2021 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Nov 10, 2021 04:05 pm ET
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m....
Nov 08, 2021 04:05 pm ET
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), today reported financial results and provided an update on corporate activities for the quarter ended September 30, 2021. “We are extremely proud of the 30% quarter-over-quarter growth in the core...
Nov 01, 2021 04:05 pm ET
Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at 4:30 p.m. EST to provide a corporate update and report its financial results for the third...
Nov 01, 2021 04:04 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Oct 18, 2021 04:05 pm ET
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium absc
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety and efficacy of NUZYRA® (omadacycline) for the treatment for nontuberculous mycobacterial...
Oct 01, 2021 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Sep 30, 2021 08:00 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021
WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will present data from their clinical and research programs at IDWeek 2021 taking place virtually from September 29-October 3, 2021. AWG members are presenting a total of 23 poster presentations and 3 oral abstract presentations.
Sep 27, 2021 04:05 pm ET
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthra
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and...
Sep 23, 2021 04:05 pm ET
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being presented at the IDWeek 2021 virtual meeting. Poster presentations will be available beginning on...
Sep 09, 2021 08:30 am ET
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Sep 01, 2021 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Aug 18, 2021 04:12 pm ET
Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA® (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 09, 2021 04:05 pm ET
Paratek Pharmaceuticals Announces Total Revenue of $57.5 Million in the Second Quarter 2021
Initiated Phase 2b Study in Non-Tuberculous Mycobacterium Abscessus BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and...
Aug 05, 2021 08:00 am ET
Acurx Pharmaceuticals Joins the Antimicrobials Working Group
WASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 13 antimicrobial drug companies.
Aug 04, 2021 04:30 pm ET
Paratek Pharmaceuticals Announces NUZYRA® (omadacycline) Has Been Added to the CDC Plague Guidelines for the Treatment, Pre-Exposure and Postexposure Prophylaxis of Plague
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for...
Aug 03, 2021 04:30 pm ET
Paratek Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 02, 2021 04:35 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Aug 02, 2021 04:30 pm ET
Paratek Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 9, 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 29, 2021 08:00 am ET
Paratek Pharmaceuticals Announces First BARDA Project BioShield Procurement of NUZYRA® (omadacycline) Valued at ~$38 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for...
Jun 21, 2021 10:55 am ET
Thinking about buying stock in Geron Corp, Ashford Hospitality Trust, Paratek Pharmaceuticals, Seanergy Maritime, or TAL Education?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GERN, AHT, PRTK, SHIP, and TAL.
Jun 16, 2021 07:30 am ET
Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Jun 14, 2021 08:00 am ET
Paratek Appoints Minnie Baylor-Henry to Company’s Board of Directors
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Jun 10, 2021 08:00 am ET
Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Jun 08, 2021 11:07 am ET
Crestone Joins Antimicrobials Working Group
WASHINGTON, June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.
Jun 01, 2021 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jun 01, 2021 07:45 am ET
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for...
May 26, 2021 04:17 pm ET
Paratek Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 17, 2021 07:30 am ET
Paratek Pharmaceuticals Announces First Quarter 2021 Total Revenue of $16.4 Million and Initiation of First BARDA Procurement
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 10, 2021 04:05 pm ET
Paratek Pharmaceuticals to Report First Quarter 2021 Financial Results on May 17, 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
May 03, 2021 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Apr 01, 2021 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Mar 01, 2021 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Feb 24, 2021 04:01 pm ET
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 18, 2021 04:01 pm ET
Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 17, 2021 04:01 pm ET
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Feb 08, 2021 08:00 am ET
Paratek Announces Expansion of NUZYRA® Launch into the Community Setting
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats in the community, hospital, and military settings, today announced the expansion of the...
Feb 01, 2021 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Jan 06, 2021 08:00 am ET
Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Jan 04, 2021 05:00 pm ET
Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Dec 01, 2020 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Nov 12, 2020 04:01 pm ET
Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Nov 05, 2020 04:01 pm ET
Paratek Pharmaceuticals Announces Third Quarter 2020 Total Revenue of $13.7 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Nov 02, 2020 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Oct 27, 2020 08:00 am ET
Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Oct 21, 2020 08:00 am ET
Paratek Pharmaceuticals Presenting New Data on NUZYRA® (Omadacycline) at IDWeek 2020
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Sep 09, 2020 04:01 pm ET
Paratek Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Sep 01, 2020 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 10, 2020 07:30 am ET
Paratek Pharmaceuticals Announces Second Quarter 2020 Total Revenue of $9.3 Million including NUZYRA® (omadacycline) Net Revenue of $8.1 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 05, 2020 04:01 pm ET
Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Aug 03, 2020 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Jul 28, 2020 04:01 pm ET
Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
May 29, 2020 08:30 am ET
Paratek Pharmaceuticals Announces Change to Time of 2020 Annual Meeting of Stockholders
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 28, 2020 08:00 am ET
Paratek Pharmaceuticals to Present at Jefferies 2020 Virtual Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 11, 2020 04:05 pm ET
Paratek Pharmaceuticals to Present at Bank of America Securities 2020 Health Care Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
May 11, 2020 06:30 am ET
Paratek Pharmaceuticals Announces First Quarter 2020 Total Revenues of $7.9 Million including NUZYRA® (omadacycline) Net Sales of $7.3 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Apr 30, 2020 08:00 am ET
Paratek Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11, 2020
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian,...
Apr 02, 2020 08:00 am ET
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for All FDA Required Post-marketing Studies for NUZYRA• (omadacycline)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Apr 01, 2020 08:00 am ET
Paratek Pharmaceuticals Announces Initiation of Funding from BARDA for Security Requirements and U.S. Onshoring of the Manufacturing Supply Chain for NUZYRA• (omadacycline)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for...
Mar 10, 2020 04:01 pm ET
Paratek Pharmaceuticals Announces the Submission of the pre-Emergency Use Authorization Application to the FDA for NUZYRA• (omadacycline)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Mar 02, 2020 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 26, 2020 08:00 am ET
Paratek Pharmaceuticals to Present at the SVB Leerink 9th Annual Global Healthcare Conference
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 25, 2020 04:01 pm ET
Paratek Pharmaceuticals Announces Full Year 2019 Total Revenues of $16.5 Million including NUZYRA® (omadacycline) Net Sales of $11.5 Million
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 24, 2020 07:00 am ET
Paratek Announces License Grant to Almirall for SEYSARA® (sarecycline) for Greater China Region
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,...
Feb 13, 2020 04:01 pm ET
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
Dec 18, 2019 05:12 pm ET
Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the Department of Health and Human Services (HHS), Office...
Dec 02, 2019 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on November 29, 2019, the Company granted stock options and...
Nov 12, 2019 04:05 pm ET
Paratek Pharmaceuticals Generates Net Revenues of $3.9 Million in the Third Quarter of 2019
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities...
Nov 04, 2019 04:05 pm ET
Paratek Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 12, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
Nov 01, 2019 04:05 pm ET
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on October 31, 2019, the Company granted stock options and...
Oct 31, 2019 04:05 pm ET
Paratek Announces Top Line Results of Phase 2 Clinical Studies of Omadacycline in Urinary Tract Infections
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced the outcome of its two exploratory Phase 2 clinical studies evaluating...
Oct 17, 2019 04:05 pm ET
Paratek Withdraws European Marketing Authorization Application for Oral and Intravenous NUZYRA in Skin Infections and Pneumonia
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the company has withdrawn its submission to the European...
Oct 01, 2019 04:30 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on September 30, 2019, the Company granted stock options...
Oct 01, 2019 10:07 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical and research programs at IDWeek 2019 to be held October 2-6, 2019 in Washington D.C.
Sep 25, 2019 08:00 am ET
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) Development Program at IDWeek 2019
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that data from its NUZYRA (omadacycline) clinical and...
Sep 09, 2019 08:00 am ET
Paratek Mourns Passing of Co-founder Dr. Stuart Levy
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) mourns the loss of Stuart Levy, M.D., who passed way last week. Dr. Levy co-founded the company more than two decades ago along with Dr. Walter Gilbert and was instrumental in the development of...
Sep 04, 2019 08:00 am ET
Paratek Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at 21st Annual H.C. Wainwright...
Sep 03, 2019 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on August 30, 2019, the Company granted stock options and...
Aug 30, 2019 08:00 am ET
The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced The Lancet Infectious Diseases published detailed results from the...
Aug 26, 2019 04:05 pm ET
Paratek Pharmaceuticals to Present at Robert W. Baird’s 2019 Global Healthcare Conference
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at Baird’s 2019 Global Healthcare...
Aug 06, 2019 04:05 pm ET
Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities...
Aug 01, 2019 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on July 31, 2019, the Company granted stock options and...
Jul 29, 2019 04:05 pm ET
Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
Jul 01, 2019 09:13 am ET
X-Biotix Therapeutics Joins Antimicrobials Working Group
WASHINGTON, July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 14 antimicrobial drug companies.
Jun 25, 2019 04:01 pm ET
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the promotion of Evan Loh, M.D., to Chief...
May 08, 2019 04:05 pm ET
Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities...
Apr 30, 2019 04:05 pm ET
Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
Apr 15, 2019 04:30 pm ET
Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
New data presented at the 29th European Congress of Clinical Microbiology & Infectious Diseases, ECCMID 2019, show that Paratek Pharmaceuticals, Inc.’s (Nasdaq:PRTK) NUZYRA™ (omadacycline) demonstrates highly potent in vitro activity against common...
Apr 12, 2019 10:08 am ET
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON, April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinical and research programs at the 29th annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2019) to be held April 13 - 16 in Amsterdam, Netherlands.  
Apr 04, 2019 08:30 am ET
Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that data from its NUZYRA™ (omadacycline) clinical and...
Apr 01, 2019 09:05 am ET
Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, announced today that the scientific team who worked on the clinical development...
Apr 01, 2019 08:10 am ET
Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Verizon Communications Inc. (NYSE:VZ), Digital Turbine, Inc. (NASDAQ:APPS),...
Mar 28, 2019 08:00 am ET
Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the H.C Wainwright Global Life...
Mar 18, 2019 08:00 am ET
Paratek Pharmaceuticals Announces Management Change
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned,...
Mar 01, 2019 04:30 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on February 28, 2019, the Company granted stock options and...
Mar 01, 2019 08:00 am ET
Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the Cowen and Company 39th...
Feb 27, 2019 04:01 pm ET
Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities...
Feb 14, 2019 04:05 pm ET
Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that the Company will present at the 8th Annual SVB Leerink...
Feb 13, 2019 04:05 pm ET
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast...
Feb 06, 2019 05:05 pm ET
New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced The New England Journal of Medicine (NEJM) today...
Feb 05, 2019 04:05 pm ET
Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced the commercial availability of NUZYRA™...
Feb 01, 2019 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on January 31, 2019, the Company granted stock options and restricted stock...
Jan 17, 2019 09:00 am ET
Antimicrobials Working Group Announces Updates to Leadership Team
WASHINGTON, Jan. 17, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr. Loh replaces Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara Therapeutics, whose two-year term as Chairman of AWG has expired. Dr. Stein will remain on the AWG Executive Committee. The AWG also announced that Ciara Kennedy, Ph.D., President and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. has been appointed as Vice Ch
Jan 02, 2019 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on December 31, 2018, the Company granted stock options and restricted stock...
Dec 06, 2018 07:30 am ET
Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc — Research Highli
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Chesapeake Utilities...
Dec 03, 2018 04:01 pm ET
Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company filed two Patent Term Extension Requests with the...
Nov 27, 2018 08:00 am ET
Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced dosing of the first patient in a Phase 2 study evaluating the...
Nov 06, 2018 04:02 pm ET
Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on financial, clinical,...
Nov 01, 2018 04:05 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that on October 31, 2018, the Company granted...
Oct 26, 2018 04:05 pm ET
Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio...
Oct 26, 2018 08:45 am ET
Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK), Dell Technologies Inc....
Oct 04, 2018 04:01 pm ET
Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline
-- EMA decision expected second half of 2019 -- BOSTON, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the acceptance of the submission to the European Medicines Agency (EMA) of the Marketing...
Oct 03, 2018 04:05 pm ET
Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that the Company will host an Investor Day on...
Oct 03, 2018 09:14 am ET
Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018
WASHINGTON, Oct. 3, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, announced today that 16 of its member companies will present data from their clinical and research programs at IDWeek 2018 to be held October 3-7 in San Francisco. AWG members are presenting a total of 40 poster presentations, four oral abstract presentations and four features within the symposium entitled "Exploring the Antibiotic Pipeline 2018."
Oct 02, 2018 06:37 pm ET
Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced that the U.S. Food and Drug Administration (FDA) has approved NUZYRA™ (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin...
Oct 02, 2018 08:45 am ET
FDA Approves SEYSARA™ (Sarecycline) for the Treatment of Moderate to Severe Acne
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Oct 01, 2018 04:01 pm ET
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, today announced that on September 28, 2018, the Company granted...
Sep 26, 2018 07:40 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Sina, Paratek Pharmaceuticals, Honda Motor Co., Prospect Capital, G1 THERAPEUTICS, and Gaming and Leisure Properties — New Research
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sina Corporation (NASDAQ:SINA), Paratek Pharmaceuticals, Inc....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.